'Fraud' Accusations Vex Valeant, Slam 'Specialty' Shares
This article was originally published in Scrip
Executive Summary
It's unclear whether it was simply another example of Valeant Pharmaceuticals International Inc.'s inability to clearly communicate or there's some actual wrongdoing going on, but the company's shares took a beating on Oct. 21, with the stock freefalling 40% – a walloping that spread to other drug makers in the sector.